Piretanide

Piretanide

File:Piretanide.png
Systematic (IUPAC) name
3-(aminosulfonyl)-4-phenoxy-5-pyrrolidin-1-ylbenzoic acid
Clinical data
Routes of administration	Oral
Legal status
Legal status	℞ (Prescription only)
Identifiers
CAS Number	55837-27-9
ATC code	C03CA03 (WHO)
PubChem	CID 4849
Chemical data
Formula	C17H18N2O5S
Molar mass	362.40 g/mol[[]]

Piretanide ([4-phenoxy-3-(1-pyrrolidinyl)-5-sulfamoyl-benzoic acid]INN) Piretanide has been synthesized in 1973 at Hoechst AG (Germany) as a diuretic and saluretic compound by using a new method for introducing cyclic amine residues in an aromatic nucleus in the presence of other aromatically bonded functional groups like sulfamoyl-, ester-,nitro-,amino-,hydroxy-,cyano-,halogen- or sulfonylimino-groups. Intensive studies of piretanide in rats and dogs in comparison with other high-ceiling diuretics e.g.furosemide and bumetanide revealed its diuretic and saluretic potency with a more suitable dose/response (regression lines) and a more favourable Na/K excretion ratio. These findings led eventually to clinical studies in man and finally to the introduction as a saluretic and antihypertensive medication in Germany,France,Italy and other countries. Trade names: ARELIX,Eurelix,Tauliz. Bibliography : W.Merkel,D.Bormann,D.Mania,R.Muschaweck and M.Hropot,EUR.J.MED.Chem.-ChIM.THER.11,399 (1976) W.Merkel,D.Mania and D.Bormann,Liebigs Ann.Chem.461(1979)

References

it:Piretanide